[Khelavaster]

> Hayashi pointed out that the key piece of evidence underpinning the previous Cochrane review’s conclusion--that Tamiflu reduced the risk of secondary complications such as pneumonia--was based on a manufacturer-authored, pooled analysis of 10 manufacturer-funded trials

Everything needed for FDA approval.

> no convincing trial evidence

It just sounds like Tamiflu efficacy studies to date haven't been thorough enough to be convincing.